Thanks Doc. I have thought about it and I guess that’s what I’m concerned about. We know that the product has essentially been improved from what Fraunhofer said. And we know that Les has attempted to characterize this as an improvement in “manufacturing methods” rather than and improvement in “product.” My question was whether you had factual knowledge that the regulators were satisfied with Les' version that the manufacturing process changes hadn’t essentially changed the quality or efficacy of the product.
That’s not what they said. Any change to the actual vaccine would require a new trial. They might have optimized a step in production but give the limited number of vaccines made in Germany, who cares?